Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Hot Flashes 1Depressive Disorder, Major 1Depression 1

Interventions

Acupuncture Therapy 5Gabapentin 4Venlafaxine Hydrochloride 3Estrogens, Conjugated (USP) 3liposomal amphotericin B 2Tamoxifen 2Magnesium Oxide 2Hypnosis 2Control Groups 2Citalopram 2oxybutynin 1black cohosh root extract 1bazedoxifene 1Zolpidem 1Testosterone 1Tablets 1Soybean Proteins 1Solifenacin Succinate 1Sodium Chloride 1Sertraline 1Progesterone 1Pregabalin 1N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine 1Mindfulness 1Mind-Body Therapies 1Megestrol Acetate 1Medroxyprogesterone 1Linseed Oil 1Isoflavones 1Hypericum extract LI 160 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hot Flashes × Escitalopram × Breast × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡